There May Be Some Bright Spots In Guangdong Hybribio BiotechLtd's (SZSE:300639) Earnings

Shareholders appeared unconcerned with Guangdong Hybribio Biotech Co.,Ltd.'s (SZSE:300639) lackluster earnings report last week. We did some digging, and we believe the earnings are stronger than they seem.

View our latest analysis for Guangdong Hybribio BiotechLtd

How Do Unusual Items Influence Profit?

For anyone who wants to understand Guangdong Hybribio BiotechLtd's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by CN¥5.5m due to unusual items. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Guangdong Hybribio BiotechLtd to produce a higher profit next year, all else being equal.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Guangdong Hybribio BiotechLtd's Profit Performance

Because unusual items detracted from Guangdong Hybribio BiotechLtd's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Guangdong Hybribio BiotechLtd's earnings potential is at least as good as it seems, and maybe even better! Unfortunately, though, its earnings per share actually fell back over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. If you'd like to know more about Guangdong Hybribio BiotechLtd as a business, it's important to be aware of any risks it's facing. While conducting our analysis, we found that Guangdong Hybribio BiotechLtd has 2 warning signs and it would be unwise to ignore them.

Today we've zoomed in on a single data point to better understand the nature of Guangdong Hybribio BiotechLtd's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.